Abstract
Introduction: The aim was to evaluate the impact of perioperative blood transfusions (PBTs) on renal function after surgery for renal cell carcinoma (RCC). Methods: Consecutive patients with RCC who underwent partial nephrectomy or radical nephrectomy between 2005 and 2015 at a tertiary care center were included. Minimum follow-up period was 6 months. A PBT was defined as the transfusion of packed erythrocyte concentrate (EC) within 7 days before until 30 days after surgery. The multivariable analyses were carried out by Cox regression. Results: The overall cohort included 851 patients, of whom 93 (10.9%) received a PBT. The median follow-up was 46 months (range 28–72). In case of a PBT, a median of 2 EC was transfused. PBT patients were older and had a poorer performance status and more comorbidities as well as locally more advanced or metastatic tumors. In the multivariable analyses, PBT was an independent prognostic factor for acute as well as chronic renal impairment (hazard ratio (HR) 2.72, 95% confidence interval (95% CI) 1.45–5.10, p = 0.002 and HR 2.23, 95% CI 1.26–3.70, p = 0.007). Conclusion: PBT is associated with acute and chronic deterioration of kidney function after surgery for RCC. Thus, it may be used to identify patients requiring close nephrological monitoring.
References
1.
Siegel
RL
, Miller
KD
, Jemal
A
. Cancer statistics, 2020
. CA Cancer J Clin
. 2020
;70
(1
):7
–30
. 2.
Klatte
T
, Ficarra
V
, Gratzke
C
, Kaouk
J
, Kutikov
A
, Macchi
V
, et al. A literature review of renal surgical anatomy and surgical strategies for partial nephrectomy
. Eur Urol
. 2015
;68
(6
):980
–92
. 3.
Arcaniolo
D
, Manfredi
C
, Cindolo
L
, Marchioni
M
, Zukovski
EP
, Mirone
V
, et al. Impact of perioperative blood transfusions on the outcomes of patients undergoing kidney cancer surgery: a systematic review and pooled analysis
. Clin Genitourin Cancer
. 2019
;17
(1
):e72
–9
. 4.
Amato
A
, Pescatori
M
. Perioperative blood transfusions for the recurrence of colorectal cancer
. Cochrane Database Syst Rev
. 2006
;2006
(1
):CD005033
. 5.
Li
SL
, Ye
Y
, Yuan
XH
. Association between allogeneic or autologous blood transfusion and survival in patients after radical prostatectomy: a systematic review and meta-analysis
. PLoS One
. 2017
;12
(1
):e0171081
. 6.
Cata
JP
, Lasala
J
, Pratt
G
, Feng
L
, Shah
JB
. Association between perioperative blood transfusions and clinical outcomes in patients undergoing bladder cancer surgery: a systematic review and meta-analysis study
. J Blood Transfus
. 2016
;2016
:9876394
. 7.
Mehta
RL
, Kellum
JA
, Shah
SV
, Molitoris
BA
, Ronco
C
, Warnock
DG
, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury
. Crit Care
. 2007
;11
(2
):R31
. 8.
Nutritional Anaemias
. Report of a WHO scientific group
. World Health Organ Tech Rep Ser
. 1968
;405
:5
–37
.9.
Delahunt
B
, Eble
JN
, Egevad
L
, Samaratunga
H
. Grading of renal cell carcinoma
. Histopathology
. 2019
;74
(1
):4
–17
. 10.
Vricella
GJ
, Finelli
A
, Alibhai
SM
, Ponsky
LE
, Abouassaly
R
. The true risk of blood transfusion after nephrectomy for renal masses: a population-based study
. BJU Int
. 2013
;111
(8
):1294
–300
. 11.
Abu-Ghanem
Y
, Dotan
Z
, Kaver
I
, Ramon
J
. Predictive factors for perioperative blood transfusions in partial nephrectomy for renal masses
. J Surg Oncol
. 2015
;112
(5
):496
–502
. 12.
Soria
F
, de Martino
M
, Leitner
CV
, Moschini
M
, Shariat
SF
, Klatte
T
. Perioperative allogenic blood transfusion in renal cell carcinoma: risk factors and effect on long-term outcomes
. Clin Genitourin Cancer
. 2017
;15
(3
):e421
–7
. 13.
Freeland
K
, Hamidian Jahromi
A
, Duvall
LM
, Mancini
MC
. Postoperative blood transfusion is an independent predictor of acute kidney injury in cardiac surgery patients
. J Nephropathol
. 2015
;4
(4
):121
–6
. 14.
Li
Y
, Li
B
, Wang
W
, Lv
J
. Risk factors for new-onset chronic kidney disease in patients who have received a liver transplant
. Exp Ther Med
. 2018
;15
(4
):3589
–95
. 15.
Lesage
K
, Joniau
S
, Fransis
K
, Van Poppel
H
. Comparison between open partial and radical nephrectomy for renal tumours: perioperative outcome and health-related quality of life
. Eur Urol
. 2007
;51
(3
):614
–20
. 16.
Webster
AC
, Nagler
EV
, Morton
RL
, Masson
P
. Chronic kidney disease
. Lancet
. 2017
;389
(10075
):1238
–52
. 17.
Hu
SL
, Chang
A
, Perazella
MA
, Okusa
MD
, Jaimes
EA
, Weiss
RH
. The nephrologist’s tumor: basic biology and management of renal cell carcinoma
. J Am Soc Nephrol
. 2016
;27
(8
):2227
–37
. 18.
Remy
KE
, Hall
MW
, Cholette
J
, Juffermans
NP
, Nicol
K
, Doctor
A
, et al. Mechanisms of red blood cell transfusion-related immunomodulation
. Transfusion
. 2018
;58
(3
):804
–15
. 19.
Arthur
CM
, Chonat
S
, Fasano
R
, Yee
MEM
, Josephson
CD
, Roback
JD
, et al. Examining the role of complement in predicting, preventing, and treating hemolytic transfusion reactions
. Transfus Med Rev
. 2019
;33
(4
):217
–24
. 20.
Park
YH
, Kim
YJ
, Kang
SH
, Kim
HH
, Byun
SS
, Lee
JY
, et al. Association between perioperative blood transfusion and oncologic outcomes after curative surgery for renal cell carcinoma
. J Cancer
. 2016
;7
(8
):965
–72
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
